Blanch, Salvador
Gil-Gil, Juan Miguel http://orcid.org/0000-0003-1380-2718
Arumí, Miriam
Aguirre, Elena
Seguí, Miguel Ángel http://orcid.org/0000-0002-5103-6746
Atienza, Manuel
Díaz-Cerezo, Silvia http://orcid.org/0000-0001-6351-818X
Molero, Alberto http://orcid.org/0000-0001-7757-5660
Cervera, José Manuel http://orcid.org/0000-0003-1674-7259
Gavilá, Joaquín
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 27 December 2022
Accepted: 18 March 2023
First Online: 7 April 2023
Declarations
:
: MaA, SD, AM and JMC are employees and shareholders of Eli Lilly and Company. SB, JMGG, MiA, MAS and JG received an economic compensation from Eli Lilly and Co. for their participation in the study (consultancy and/or data collection tasks).
: AbemusS was conducted in accordance with Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. The study was approved by the accredited independent ethics committee (IEC) of the Instituto Valenciano de Oncología of Valencia (IVO).
: This was an observational study that used data previously collected and did not impose any form of intervention, the data was deidentified to protect subject privacy. A formal consent to release information form was not required from the Ethics Committee of Instituto Valenciano de Oncología of Valencia (IVO).